Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882557 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
A Phase 1 study of End Stage Renal Disease and Renal Failure Chronic Requiring Hemodialysis, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT00882557: Completed Phase 1 study of End Stage Renal Disease and Renal Failure Chronic Requiring Hemodialysis, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT00882557 is a Phase 1 study of End Stage Renal Disease and Renal Failure Chronic Requiring Hemodialysis that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 16 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00882557, a Phase 1 study of End Stage Renal Disease and Renal Failure Chronic Requiring Hemodialysis, has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.
Primary Outcome
Area under the plasma concentration versus time curve from time 0 to infinity for daptomycin doses
Conditions Studied
Interventions
- DRUG daptomycin
Study Locations (2)
California
- West Coast Clinical Trials - Cypress
Minnesota
- DaVita Clinical Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-04-29 |
| Est. Completion | 2009-07-17 |
| Phase | Phase 1 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
What the finished NCT00882557 record still lists
NCT00882557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which daptomycin is the first listed.
NCT00882557 reports a single indexed study location in California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00882557 about?
NCT00882557 is a clinical study titled "Study to Evaluate Daptomycin Given During Dialysis and After Dialysis". The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.
What is the current status of trial NCT00882557?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-04-29. Estimated completion is 2009-07-17.
What conditions does trial NCT00882557 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis.
What interventions are being tested in trial NCT00882557?
The interventions under investigation include: daptomycin (DRUG).
Who is sponsoring clinical trial NCT00882557?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00882557 being conducted?
This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00882557's enrollment target sits among peer trials
16 72nd of 86 higher than 14 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI